Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 3 trial shows ecopipam, a novel non-antipsychotic drug, slashed tic relapse risk by 50% in pediatric Tourette syndrome patients compared to placebo. Unlike traditional D2-targeting antipsychotics, ecopipam selectively targets dopamine D1 receptors, avoiding weight gain and metabolic side effects. The drug has received FDA Priority Review and Orphan Drug designation for pediatric use.
A phase 3 randomized withdrawal trial (D1AMOND) found that ecopipam — an investigational selective dopamine D1 receptor antagonist — was associated with a 50% lower risk of tic relapse compared to placebo in pediatric patients with Tourette syndrome. A companion review in the Journal of Child Neurology situates these results within a broader body of phase 2b, phase 3, and long-term open-label data, framing D1 receptor antagonism as a promising non-antipsychotic approach to tic management.
What sets ecopipam apart is its mechanism: rather than targeting D2 receptors like conventional antipsychotics, it acts on D1 receptors in the direct motor pathway — potentially delivering tic control without the metabolic side effects typically associated with D2-targeting agents.
By the Numbers
Why it matters: Tourette syndrome management in children has long been constrained by the side effect profiles of available therapies. Ecopipam's cleaner safety profile — particularly the absence of weight gain and metabolic effects — could make it a meaningful option for young patients, pending FDA approval.
